Global Hepatitis B Vaccines Market Growth 2023-2029

Global Hepatitis B Vaccines Market Growth 2023-2029

Hepatitis B vaccine is a vaccine that prevents hepatitis B.
LPI (LP Information)' newest research report, the “Hepatitis B Vaccines Industry Forecast” looks at past sales and reviews total world Hepatitis B Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Hepatitis B Vaccines sales for 2023 through 2029. With Hepatitis B Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatitis B Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Hepatitis B Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatitis B Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Hepatitis B Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis B Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis B Vaccines.
The global Hepatitis B Vaccines market size is projected to grow from US$ 999.6 million in 2022 to US$ 1137.8 million in 2029; it is expected to grow at a CAGR of 1137.8 from 2023 to 2029.
In the last several years, Global market of Hepatitis B vaccine developed smoothly, with an average growth rate of -0.32%.
The classification of Hepatitis B vaccine includes Yeast Derived, CHO Derived, and the sales proportion of Yeast Derived in 2019 is about 97%. Hepatitis B vaccine is widely used for Children and Adult. About 84% of Hepatitis B vaccine is used for Children.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 50% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of nearly 30%.
Market competition is intense. GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis B Vaccines market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Yeast Derived
CHO Derived
Segmentation by application
Children
Adult
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute

Key Questions Addressed in this Report
What is the 10-year outlook for the global Hepatitis B Vaccines market?
What factors are driving Hepatitis B Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hepatitis B Vaccines market opportunities vary by end market size?
How does Hepatitis B Vaccines break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.